Opinion|Videos|January 16, 2024
Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting
Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5